Comparative Pharmacology
Head-to-head clinical analysis: INGREZZA SPRINKLE versus VALBENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INGREZZA SPRINKLE versus VALBENAZINE.
INGREZZA SPRINKLE vs VALBENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INGREZZA SPRINKLE contains valbenazine, a selective VMAT2 inhibitor that reduces the release of dopamine into the synaptic cleft, thereby decreasing dopaminergic neurotransmission in the striatum. The exact mechanism for the treatment of tardive dyskinesia is unknown but is thought to involve modulation of dopamine signaling.
Vesicular monoamine transporter 2 (VMAT2) inhibitor, reducing dopamine release in the striatum.
Initial dose: 40 mg orally once daily (as 1 capsule of INGREZZA SPRINKLE 40 mg or 4 capsules of 10 mg). After 1 week, increase to target dose of 80 mg orally once daily (as 2 capsules of 40 mg or 8 capsules of 10 mg). Capsules may be swallowed whole or opened and sprinkled onto soft food.
50 mg orally once daily; can be increased to 75 mg orally once daily based on tolerability and response.
None Documented
None Documented
Clinical Note
moderateValbenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Cyclosporine
17-20 hours; steady state reached in approximately 5 days.
Terminal elimination half-life is approximately 17-23 hours, allowing for once-daily dosing.
60% renal (as unchanged drug and metabolites), 40% fecal (as metabolites).
Primarily hepatic metabolism; less than 30% of the dose excreted unchanged in urine and feces combined. Biliary/fecal excretion accounts for approximately 40-60% as metabolites.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Valbenazine."